Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol:AC STAGE IV





Adriamycin & Cyclophosphamide

IDENTIFICATION: Combination chemotherapy with cyclophosphamide (Cytoxan) and doxorubicin (adriamycin); also called "AC"
These drugs have been approved by the FDA (Food and Drug Administration) for the treatment of breast cancer.
DOSES: Cyclophosphamide 600 mg/M2, Adriamycin 60 mg/M2
ROUTE: Intravenously (IV)
DURATION AND TIMING: Given once every 21 days. Treatments are generally continued if the drug keeps the breast cancer from growing unless there are unacceptable side effects.
Possible Side effects:
  • Hematopoetic: decrease in blood cells, especially white cells (neutropenia) but also red cells (anemia) and/or platelets (thrombocytopenia).
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications); diarrhea; mouth sores; decreased appetite.
  • Integmentary: severe hair loss; dry skin, nail thinning or ridging.
  • Genitourinary: cytoxan may cause irritation to the kidneys or bladder.
  • Fertility: cytoxan may cause damage to the ovaries of premenopausal women. This may lead to temporary or permanent infertility. Patients may also develop an early menopause.
  • Cardiovascular: adriamycin may cause a weakening of the heart muscle. In severe cases this may result in congestive heart failure. This may occur in less than 1% of patients receiving standard doses.
  • Neurological: some patients complain of a decrease in their ability to concentrate and/or remember, which improves on completion of therapy.
  • Other: some patients complain of taste changes and/or lack of appetite.

Back gif


1997 - TransMed Network